PMSF Welcomes Christopher Winrow, PhD, to Board of Directors
The Phelan-McDermid Syndrome Foundation (PMSF) is pleased to announce the appointment of Christopher Winrow, PhD, to its Board of Directors, effective…
The Phelan-McDermid Syndrome Foundation (PMSF) is pleased to announce the appointment of Christopher Winrow, PhD, to its Board of Directors, effective…
In 2025, families found connection, care expanded, and research accelerated, bringing treatments and a cure closer than ever.
The Phelan-McDermid Syndrome Foundation’s 2025 Independent Audit Report provides an objective assessment of the organization’s financial statements and internal controls.
The Phelan-McDermid Syndrome Foundation (PMSF) is committed to transparency and responsible stewardship.
The Phelan McDermid Syndrome Foundation (PMSF) today announced the appointment of Robbie Baker, a seasoned nonprofit executive and successful fundraiser, as its new Chief Executive Officer.
A new FAQ from Jaguar Gene Therapy is now available, including updated details about the JAG201 clinical study. This FAQ addresses…
This one-page information sheet provides a brief overview of Phelan-McDermid syndrome, including its genetics, symptoms, treatments, and how the Phelan-McDermid Syndrome…
Phelan-McDermid syndrome is characterized by global developmental delay, intellectual disability, speech impairment, autism spectrum disorder, and hypotonia; other variable features include epilepsy, brain and renal malformations, and mild dysmorphic features. Here, we conducted genotype-phenotype correlation analyses using the PMS International Registry, a family-driven registry that compiles clinical data in the form of family-reported outcomes and family-sourced genetic test results.
Phelan-McDermid Syndrome Foundation, Inc. Independent Auditor’s Report, Financial Statements For the years ended December 31, 2023 and 2022
Phelan-McDermid Syndrome Foundation (PMSF) 990 Tax Form